Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
Opioid Crisis Deepens as Teva, Allergan Face Fraud Charges
by Kinjel Shah
The DFS charges claim that Teva (TEVA) and Allergan (AGN) used fraudulent marketing and promotional campaigns to promote their opioid products
FDA Nods to Emergent's (EBS) Narcan Shelf Life Extension
by Zacks Equity Research
Emergent's (EBS) Narcan nasal spray gets an FDA nod to extend its shelf life from two years to three years.
Teva (TEVA) Q2 Earnings Top, Stock Up Despite Coronavirus Woes
by Zacks Equity Research
Teva (TEVA) beats second-quarter estimates for earnings while missing the same for sales. It maintains its previously issued guidance for 2020. Stock up.
Perrigo (PRGO) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.
Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.
Teva (TEVA) Q2 Earnings Beat, Sales Miss, Keeps 2020 View
by Zacks Equity Research
Teva beats estimates for earnings while missing the same for sales in second-quarter 2020. It maintains its previously issued guidance for 2020. Stock up.
Teva (TEVA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Uncertainty Looms Large Over Generic Drug Industry Players
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs lead to recovery in the industry. New launches also provide a boost. However, coronavirus crisis creates an uncertainty for the industry.
The Zacks Analyst Blog Highlights: Canadian Solar, Office Depot and Teva Pharmaceutical Industries
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Canadian Solar, Office Depot and Teva Pharmaceutical Industries
Sometimes, Valuation Is the Most Important Consideration
by Sejuti Banerjea
It pays to check the valuation before investing because it isn't always the best companies that have upside potential.
FDA Advisory Committee to Review Mallinckrodt'sTerlipressin
by Zacks Equity Research
Mallinckrodt (MNK) announces that the Cardiovascular and Renal Drugs Advisory Committee of the FDA will hold a virtual meeting to review data on terlipressin.
Endo (ENDP) Obtains FDA Approval for Cellulite Treatment
by Zacks Equity Research
Endo (ENDP) gains FDA approval for Qwo (collagenase clostridium histolyticum-aaes) for the treatment of cellulite.
Pick These 4 Low P/CF Stocks for a Balanced Portfolio in 2H
by Sumit Singh
Investment in stocks made on diligent value analysis is usually considered one of the best practices. In value investing, investors pick stocks that are cheap but fundamentally sound.
Choose These 5 Price-to-Book Value Stocks for High Returns
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TEVA) Outperforming Other Medical Stocks This Year?
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Novartis Discontinues HCQ Study Due to Enrollment Challenges
by Zacks Equity Research
Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.
FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus
by Kinjel Shah
The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.
Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TEVA) Outperforming Other Medical Stocks This Year?
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $11.25, moving -0.71% from the previous trading session.
Emergent (EBS) Down on Unfavorable Patent Ruling on Narcan
by Zacks Equity Research
Emergent's (EBS) stock falls after a district court rules against the patent litigation on its Narcan nasal spray product. The court ruled in favor of Teva Pharmaceuticals, the defendants.
Novartis' sBLA for Ofatumumab Gets Extended Review From FDA
by Zacks Equity Research
The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.
Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.